Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 1
2004 3
2005 8
2006 4
2007 3
2008 4
2009 12
2010 20
2011 19
2012 17
2013 9
2014 8
2015 10
2016 8
2017 7
2018 10
2019 9
2020 9
2021 15
2022 16
2023 10
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

175 results

Results by year

Filters applied: . Clear all
Page 1
Cannabidiol for the treatment of autism spectrum disorder: hope or hype?
Pedrazzi JFC, Ferreira FR, Silva-Amaral D, Lima DA, Hallak JEC, Zuardi AW, Del-Bel EA, Guimarães FS, Costa KCM, Campos AC, Crippa ACS, Crippa JAS. Pedrazzi JFC, et al. Among authors: zuardi aw. Psychopharmacology (Berl). 2022 Sep;239(9):2713-2734. doi: 10.1007/s00213-022-06196-4. Epub 2022 Jul 29. Psychopharmacology (Berl). 2022. PMID: 35904579 Review.
Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report.
Crippa JA, Derenusson GN, Ferrari TB, Wichert-Ana L, Duran FL, Martin-Santos R, Simões MV, Bhattacharyya S, Fusar-Poli P, Atakan Z, Santos Filho A, Freitas-Ferrari MC, McGuire PK, Zuardi AW, Busatto GF, Hallak JE. Crippa JA, et al. J Psychopharmacol. 2011 Jan;25(1):121-30. doi: 10.1177/0269881110379283. Epub 2010 Sep 9. J Psychopharmacol. 2011. PMID: 20829306 Clinical Trial.
Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients.
Bergamaschi MM, Queiroz RH, Chagas MH, de Oliveira DC, De Martinis BS, Kapczinski F, Quevedo J, Roesler R, Schröder N, Nardi AE, Martín-Santos R, Hallak JE, Zuardi AW, Crippa JA. Bergamaschi MM, et al. Neuropsychopharmacology. 2011 May;36(6):1219-26. doi: 10.1038/npp.2011.6. Epub 2011 Feb 9. Neuropsychopharmacology. 2011. PMID: 21307846 Free PMC article. Clinical Trial.
The role of inflammation in schizophrenia: an overview.
Chaves C, Zuardi AW, Hallak JE. Chaves C, et al. Among authors: zuardi aw. Trends Psychiatry Psychother. 2015 Apr-Jun;37(2):104-5. doi: 10.1590/2237-6089-2015-0007. Trends Psychiatry Psychother. 2015. PMID: 26222303 Free article. Review. No abstract available.
The Effect of Cannabidiol for Restless Legs Syndrome/Willis-Ekbom Disease in Parkinson's Disease Patients with REM Sleep Behavior Disorder: A Post Hoc Exploratory Analysis of Phase 2/3 Clinical Trial.
de Almeida CMO, Brito MMC, Bosaipo NB, Pimentel AV, Sobreira-Neto MA, Tumas V, Zuardi AW, Crippa JAS, Hallak JEC, Eckeli AL. de Almeida CMO, et al. Cannabis Cannabinoid Res. 2023 Apr;8(2):374-378. doi: 10.1089/can.2021.0158. Epub 2022 Jun 24. Cannabis Cannabinoid Res. 2023. PMID: 35749710 Clinical Trial.
Cannabidiol monotherapy for treatment-resistant schizophrenia.
Zuardi AW, Hallak JE, Dursun SM, Morais SL, Sanches RF, Musty RE, Crippa JA. Zuardi AW, et al. J Psychopharmacol. 2006 Sep;20(5):683-6. doi: 10.1177/0269881106060967. Epub 2006 Jan 9. J Psychopharmacol. 2006. PMID: 16401651 Clinical Trial.
175 results